Association between Antiepileptic Drugs and Incident Parkinson's Disease among Patients Followed in German Primary Care Practices
Por:
Kostev K, Doege C, Jacob L., Smith L, Koyanagi A, Gollop C and Schrag A
Publicada:
1 mar 2023
Ahead of Print:
6 mar 2023
Categoría:
Neuroscience (miscellaneous)
Resumen:
Background: The aim of this study was to analyze whether prescriptions of antiepileptic drugs (AEDs) are significantly associated with an increased incidence of Parkinson's disease (PD) in the German population. Methods: This study used data from German primary care practices found in the Disease Analyzer database (IQVIA) and included all patients aged >= 18 years who were diagnosed with PD between January 2010 and December 2021 (index date). The controls were patients without PD matched (1:1) by age, sex, and pre-diagnostic observation time in years. Associations between AED prescriptions (any AED as well as separate evaluations for carbamazepine, lamotrigine, levetiracetam, sodium valproate, gabapentin, and pregabalin) and subsequent diagnosis of PD were examined using a logistic regression model adjusted for epilepsy, restless legs syndrome, and neuropathy diagnoses. Results: We identified 24,950 cases that were matched with 24,950 controls (mean age 75.2 years, 47.3% women). Diagnoses of epilepsy, restless legs syndrome, and neuropathy as well as AED prescription were significantly associated with an increased incidence of PD. In the multivariate analysis, incidence of PD was significantly associated with epilepsy (OR: 1.91; 95% CI: 1.69-2.15), restless legs syndrome (OR: 3.02; 95% CI: 2.73-3.34), and neuropathy (OR: 1.53; 95% CI: 1.44-1.62)), as well as the prescription of any AED (OR: 1.43; 95% CI: 1.33-1.53), sodium valproate (OR: 2.39; 95% CI: 1.84-3.11), gabapentin (OR: 1.36; 95% CI: 1.22-1.52), and pregabalin (OR: 1.28; 95% CI: 1.15-1.41). Conclusion: Prescriptions of AEDs, including sodium valproate, gabapentin, and pregabalin, were associated with an increased risk of subsequent PD, even after adjustment for underlying diagnoses. Further studies are needed to confirm the present results.
Filiaciones:
Kostev K:
University Clinic, Philipps University, 35043 Marburg, Germany
Epidemiology, IQVIA, 60549 Frankfurt, Germany
Doege C:
Department of Pediatric Neurology, Center for Pediatrics and Adolescent Medicine, Central Hospital, 28211 Bremen, Germany
Jacob L.:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, 42, Sant Boi de Llobregat, 08830 Barcelona, Spain
Department of Physical Medicine and Rehabilitation, Lariboisière-Fernand Widal Hospital, AP-HP, Paris Cité University, 75010 Paris, France
Smith L:
Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge CB1 1PT, UK
Koyanagi A:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, 42, Sant Boi de Llobregat, 08830 Barcelona, Spain
Institució Catalana de Recerca i Estudis Avançats (ICREA), Pg. Lluis Companys 23, 08830 Barcelona, Spain
Gollop C:
Epidemiology, IQVIA, 60549 Frankfurt, Germany
Schrag A:
Neurology, University College London, London WC1N 3BG, UK
gold, Green Published, Green Accepted
|